BPR-30901649

BPR-30901649 is an investigational small interfering RNA (siRNA) therapeutic being developed by Betterima (a subsidiary of Better Pharmaceutical) for the treatment of mild primary hypertension. Developed using Betterima's proprietary small nucleic acid platform, BPR-30901649 is designed to target and silence a specific gene involved in blood pressure regulation (likely angiotensinogen, AGT, based on the company's patent portfolio). It is administered via subcutaneous injection. In late 2026, Betterima initiated a Phase I randomized, double-blind, placebo-controlled clinical trial in China to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and blood pressure-lowering effects of BPR-30901649 in Chinese adults with mild primary hypertension.